Pfizer stock on watch as R&D head to depart (NYSE:PFE)
seekingalpha.com • 588 days
Low Materiality0/10
Information
Pfizer's (PFE) Chief Scientific Officer, Mikael Dolsten, is leaving after 15 years.
Original sourceAI Summary
Pfizer's Chief Scientific Officer and President of R&D, Mikael Dolsten, to leave after 15 years. External search for a new Chief Scientific Officer expected to last until early next year. Dolsten joined Pfizer in 2009 through the Wyeth acquisition, oversaw approval of 35 drugs and vaccines.
Market-Moving
- Pfizer's Chief Scientific Officer and President of R&D, Mikael Dolsten, to leave after 15 years.
- External search for a new Chief Scientific Officer expected to last until early next year.
- Dolsten joined Pfizer in 2009 through the Wyeth acquisition, oversaw approval of 35 drugs and vaccines.
Key Facts
- Pfizer's Chief Scientific Officer and President of R&D, Mikael Dolsten, to leave after 15 years.
- External search for a new Chief Scientific Officer expected to last until early next year.
- Dolsten joined Pfizer in 2009 through the Wyeth acquisition, oversaw approval of 35 drugs and vaccines.